Skip to main
WGS
WGS logo

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 13%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp has demonstrated a solid performance, with total revenue reaching $87.1 million, reflecting a significant 42% year-over-year growth, which surpassed consensus expectations by approximately 9%. The company is positioned for substantial growth with projected volume increases of around 30% year-over-year in Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), alongside a notable 62% year-over-year revenue increase in these areas. Strategic improvements in reimbursement processes, cost synergies through automation, and a robust data advantage in rare diseases are expected to contribute to GeneDx's long-term value and success in the evolving precision medicine landscape.

Bears say

GeneDx Holdings Corp has experienced a concerning decline in 1Q whole exome sequencing (WES) and whole genome sequencing (WGS) volumes, which fell 1% quarter-over-quarter despite a year-over-year increase of 24%. Following a first-quarter earnings beat that did not meet elevated investor expectations, the company's stock saw a significant decline of approximately 43%. Analysts have lowered the price target, reflecting heightened risks associated with slower-than-expected growth in testing volumes, competitive pressures, and potential obstacles in health system partnerships and reimbursement challenges.

WGS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 13% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Buy based on their latest research and market trends.

According to 8 analysts, WGS has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.